These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29952529)

  • 1. Combined use of an ACE-inhibitor and spironolactone in patients with heart insufficiency.
    Schröder J; Goltz L; Knoth H
    Med Monatsschr Pharm; 2017 Jan; 40(1):24-6. PubMed ID: 29952529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I; Yalcin S; Ozhan H
    Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dangerous hyperkalemia as sequelae of new treatment strategies of heart failure].
    Fuster D; Frey FJ; Ferrari P
    Praxis (Bern 1994); 2000 Dec; 89(49):2073-6. PubMed ID: 11190849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study.
    Juurlink DN; Mamdani MM; Lee DS; Kopp A; Austin PC; Laupacis A; Redelmeier DA
    N Engl J Med; 2004 Aug; 351(6):543-51. PubMed ID: 15295047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.
    Dinsdale C; Wani M; Steward J; O'Mahony MS
    Age Ageing; 2005 Jul; 34(4):395-8. PubMed ID: 15955761
    [No Abstract]   [Full Text] [Related]  

  • 12. Elderly heart failure patients with drug-induced serious hyperkalemia.
    Vanpee D; Swine CH
    Aging (Milano); 2000 Aug; 12(4):315-9. PubMed ID: 11073352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spironolactone in severe heart failure: enhances efficacy of diuretic + ACE inhibitor combinations.
    Prescrire Int; 2000 Oct; 9(49):158-9. PubMed ID: 11603418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
    Pitt B; Zannad F; Remme WJ; Cody R; Castaigne A; Perez A; Palensky J; Wittes J
    N Engl J Med; 1999 Sep; 341(10):709-17. PubMed ID: 10471456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone for heart failure.
    Med Lett Drugs Ther; 1999 Sep; 41(1061):81-2. PubMed ID: 10505071
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.
    Cruz CS; Cruz AA; Marcílio de Souza CA
    Nephrol Dial Transplant; 2003 Sep; 18(9):1814-9. PubMed ID: 12937229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperkalemia in ambulant postcardiac surgery patients during combined therapy with angiotensin-converting enzyme inhibitor, spironolactone, and diet rich in potassium: A report of two cases and review of literature.
    Dixit A; Majumdar G; Tewari P
    Ann Card Anaesth; 2019; 22(2):162-168. PubMed ID: 30971598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H; Vanholder R; Billiouw JM; Lameire N
    Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety of spironolactone treatment in patients with heart failure.
    Anton C; Cox AR; Watson RD; Ferner RE
    J Clin Pharm Ther; 2003 Aug; 28(4):285-7. PubMed ID: 12911680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.